AZD0120
Sponsors
AstraZeneca AB, AstraZeneca, Alexion Pharmaceuticals, Inc., Tongji Hospital
Conditions
AmyloidosisHighly Sensitized Patients Awaiting Kidney TransplantIdiopathic Inflammatory MyopathiesLight Chain AmyloidosisLupus Erythematosus, SystemicMultiple MyelomaRefractory AL AmyloidosisRelapsed AL Amyloidosis
Early Phase 1
Phase 1
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingNCT05850234
Start: 2023-07-20End: 2028-11-14Target: 182Updated: 2026-05-06
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RecruitingNCT06897930
Start: 2025-04-21End: 2029-05-01Target: 150Updated: 2026-05-12
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
RecruitingNCT07073547
Start: 2025-07-31End: 2028-05-26Target: 40Updated: 2026-04-28
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingNCT07081646
Start: 2025-08-18End: 2031-02-14Target: 91Updated: 2026-03-24
A Study of AZD0120 in Autoimmune Diseases
RecruitingNCT07295847
Start: 2026-01-09End: 2028-02-22Target: 27Updated: 2026-05-01
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingNCT07391657
Start: 2026-02-23End: 2030-08-12Target: 508Updated: 2026-04-30
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Not yet recruitingCTIS2025-523285-25-00
Target: 38Updated: 2026-04-30